Brief: Better Therapeutics Submits De Novo Request To U.S. FDA For BT-001 Investigational Prescription Digital Therapy For Type 2 Diabetes

Better Therapeutics

22/09/2022 13:06

Sept 22 (Reuters) - Better Therapeutics Inc  BTTX.O :
    * BETTER THERAPEUTICS SUBMITS DE NOVO REQUEST TO U.S. FDA
FOR
BT-001 INVESTIGATIONAL PRESCRIPTION DIGITAL THERAPY FOR TYPE 2
DIABETES
    * BETTER THERAPEUTICS INC - SUBMISSION FOLLOWS COMPLETION OF
FIRST-IN-CLASS TRIAL DEMONSTRATING IMPROVEMENTS IN A1C REDUCTION
WITH INVESTIGATIONAL THERAPY TARGETING  CAUSES OF TYPE 2
DIABETES
    * BETTER THERAPEUTICS INC - IF AUTHORIZED BY FDA, BT-001
WOULD BE
FIRST VALIDATED, PRESCRIPTION SOLUTION FOR DELIVERING CBT TO T2D
PATIENTS AT SCALE
    * BETTER THERAPEUTICS INC - BT-001 RESULTS ACHIEVED WERE
SUSTAINABLE AND IMPROVED BETWEEN DAY 90 AND DAY 180 OF TRIAL

Source text for Eikon:  ID:nBw5vXTc5a 
Further company coverage:  BTTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))